Related Experiment Video
Updated: Aug 17, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Clinical and economic effects of pertussis outbreaks
1Bureau of Communicable Diseases and Preparedness, Wisconsin Division of Public Health, Madison, WI 53702, USA. davisjp@dhfs.state.wi.us
Background:
The reported incidence of pertussis is increasing, especially among the adolescent population. Current outbreak management strategies include investigating cases, contact follow-up, diagnostic testing, and antibiotic prophylaxis and treatment. The cost of these methods is substantial and can be attributed to the mobilization within public health departments to control the outbreaks.
Methods:
Through an extensive review of the literature, the clinical and economic effects of pertussis outbreaks in various nonhousehold settings are discussed.
Results:
The reported incidence of pertussis among adolescents and adults in the United States since the early 1980s continues to rise. The challenges of preventing and controlling pertussis outbreaks involve diagnosing pertussis in a timely, accurate, and standardized fashion and understanding the true burden of disease in different age and socioeconomic groups. The economic effects of pertussis have been demonstrated to be significant to individuals and communities, both locally and globally. Costs associated with pertussis often include diagnostic testing, hospitalization, emergency and/or medical office visits, antibiotic and symptomatic treatment, lost work days, and other reductions in productivity. In outbreak settings, increased surveillance, antibiotic prophylaxis, isolation of infected cases, and enhanced communication and education add to the economic burden of this disease. The potential opportunity to apply the use of pertussis booster vaccination to these populations, particularly among adolescents, likely would reduce the occurrence of pertussis and minimize the clinical and economic repercussions of pertussis outbreaks.
Conclusions:
In the near future, it is anticipated that evaluating the effects of a licensed acellular pertussis booster vaccine in persons > or =10 years of age will become routine in pertussis prevention and outbreak-control activities.
Related Concept Videos
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Pneumonia II: Pathophysiology
Investigation of Disease Outbreaks
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Respiratory Syncytial Virus Disease
